For more than two decades, Catalent Biologics has built capabilities and experience in development, manufacturing, and analytical services for new biological entities, gene therapies, biosimilars, and antibody-drug conjugates. The company has worked with 600+ mAbs and 80+ proteins, and more than 120 active clinical trials and 13 marketed products have used GPEx® cell line engineering technology. A further 35+ commercially-approved products have employed Catalent Biologics’ capabilities through to drug product fill/finish.
Catalent Cell & Gene Therapy, a unit of Catalent Biologics, is a full-service partner for adeno-associated virus (AAV) vectors and CAR-T immunotherapies, with deep experience in viral vector scale-up and production. Catalent recently acquired MaSTherCell, adding expertise in autologous and allogeneic cell therapy development and manufacturing. Catalent has produced 100+ cGMP batches across 70+ clinical and commercial programs.
Using advanced technology and tailored solutions for clinical through commercial supply, Catalent Biologics brings better biologic treatments to patients, faster.